BPGbio Appoints Esteemed Cancer Researcher Dr. Dipanjan Chowdhury to Scientific Advisory Board
July 08 2024 - 7:00AM
Business Wire
Appointment Enhances Leadership in Protein
Homeostasis and Oncology Translational Medicine
BPGbio, Inc., a leading biology-first, AI-powered, clinical
stage biopharma focused on mitochondrial biology and protein
homeostasis, today announced the addition of Dr. Dipanjan
Chowdhury, a distinguished cancer researcher, to its Advisory
Board. With his extensive expertise in early translational research
and a deep understanding of aggressive solid tumors, Dr. Chowdhury
will provide valuable guidance to enhance BPGbio’s preclinical and
clinical development processes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240708275532/en/
Dipanjan Chowdhury, Ph.D. (Photo:
Business Wire)
Dr. Dipanjan Chowdhury, an expert in cancer therapy, currently
serves as the Chief of the Division of Radiation and Genome
Stability at the Dana-Farber Cancer Institute, and is a Professor
of Radiation Oncology at Harvard Medical School. His groundbreaking
research on DNA damage repair mechanisms has significantly advanced
the field of cancer therapy, earning him numerous accolades and
recognition in the scientific community. Leading The Chowdhury Lab
at Dana-Farber, Dr. Chowdhury focuses on understanding the
mechanisms of DNA repair and how these processes influence cancer
development and treatment. His lab has identified key proteins in
the DNA damage response and clarified their roles in maintaining
genomic stability, which is critical for developing novel cancer
therapies to enhance the effectiveness of existing treatments and
overcome resistance.
“It’s a privilege to have Dr. Chowdhury join our Scientific
Advisory Board,” said Niven R. Narain, Ph.D., Chairman, President
and CEO of BPGbio. “BPGbio’s NAi platform generates a vast amount
of potential novel targets, including groundbreaking ones in our E2
protein degraders program that aims to identify ways to target
pathways long considered undruggable. Dr. Chowdhury’s expertise in
translational cancer research related to proteins will be very
valuable in helping us perfect our target validation process.”
“The team at BPGbio is at the forefront of advancing medicines
on highly aggressive cancer phenotypes through their pioneering
work in mitochondrial biology and protein homeostasis,” said Dr.
Chowdhury. “I look forward to contributing to the company's
innovative efforts and helping to drive forward BPGbio’s mission of
developing breakthrough therapies for patients for unmet
needs.”
About BPGbio Inc.
BPGbio is a leading biology-first AI-powered clinical stage
biopharma focused on mitochondrial biology and protein homeostasis.
The company has a deep pipeline of AI-developed therapeutics
spanning oncology, rare disease and neurology, including several in
late-stage clinical trials. BPGbio’s novel approach is underpinned
by NAi, its proprietary Interrogative Biology Platform, protected
by over 400 US and international patents; one of the world’s
largest clinically annotated non-governmental biobanks with
longitudinal samples; and exclusive access to the most powerful
supercomputer in the world. With these tools, BPGbio is redefining
how patient biology can be modeled using bespoke Bayesian AI
specifically designed for solving large-scale biology challenges.
Headquartered in greater Boston, the company is at the forefront of
a new era in medicine, combining biology, multi-modal data, and AI
to transform the way we understand, diagnose, and treat disease.
For more information, visit www.bpgbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708275532/en/
media@bpgbio.com